Zai Lab and Novocure Awarded Deal of the Year Read more about Zai Lab and Novocure Awarded Deal of the Year
Zai Lab Limited Announces Presentations at November Conferences Read more about Zai Lab Limited Announces Presentations at November Conferences
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong Read more about Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Read more about Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence Read more about Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence
Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology Read more about Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology Read more about Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable Read more about Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable
Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China Read more about Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Read more about Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China